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Abstract
Toxoplasma gondii infects up to one third of the world’s population. A key to the success of T. gondii as a parasite is its
ability to persist for the life of its host as bradyzoites within tissue cysts. The glycosylated cyst wall is the key structural
feature that facilitates persistence and oral transmission of this parasite. Because most of the antibodies and reagents that
recognize the cyst wall recognize carbohydrates, identification of the components of the cyst wall has been technically
challenging. We have identified CST1 (TGME49_064660) as a 250 kDa SRS (SAG1 related sequence) domain protein with a
large mucin-like domain. CST1 is responsible for the Dolichos biflorus Agglutinin (DBA) lectin binding characteristic of T.
gondii cysts. Deletion of CST1 results in reduced cyst number and a fragile brain cyst phenotype characterized by a thinning
and disruption of the underlying region of the cyst wall. These defects are reversed by complementation of CST1. Additional
complementation experiments demonstrate that the CST1-mucin domain is necessary for the formation of a normal cyst
wall structure, the ability of the cyst to resist mechanical stress, and binding of DBA to the cyst wall. RNA-seq transcriptome
analysis demonstrated dysregulation of bradyzoite genes within the various cst1 mutants. These results indicate that CST1
functions as a key structural component that confers essential sturdiness to the T. gondii tissue cyst critical for persistence of
bradyzoite forms.
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Introduction
Toxoplasma gondii, an Apicomplexan, is an obligate intracellular
protozoan parasite that can cause severe human disease. It is
estimated that a third of the human population is chronically
infected with T. gondii [1], with prevalence rates ranging from a
few percent to nearly 80% depending on the population [2]. This
parasite can cause lethal encephalitis in immune compromised
individuals such as those with AIDS or organ transplant recipients
on immune suppressive medications. It is also the cause of a
devastating congenital disease, which may result in blindness and
mental retardation if infection occurs in a T. gondii seronegative
pregnant woman. During acute infection, the parasites proliferate
as the fast-growing tachyzoite life cycle form, which causes a
disseminated systemic infection. This disseminated acute infection
is controlled by interferon-c and T cell responses. In response to
stress signals during acute infection, such as the immune response
or programmed spontaneous differentiation responses, tachyzoites
differentiate into the slow-growing bradyzoite life cycle stage that
remains latent in the host. Bradyzoites can form tissue cysts in
brain, muscles and visceral organs and when tissue cysts are orally
ingested the released bradyzoites differentiate into tachyzoites,
causing an acute infection in a new host. Bradyzoite differentiation
processes and the development and maintenance of tissue cysts are
critical for transmission of T. gondii infection. Evidence suggests
that the latent tissue cysts evade the immune response [3] and
can persist for the host life span [4]. It is likely tissue cysts
occasionally rupture and any released parasites [5] are cleared
by immune system. In the absence of an effective immune
response these released organisms can differentiate into tachyzoites
causing an acute infection. Thus, tissue cysts serve as reservoir for
the reactivation of the toxoplasmosis when the host becomes
immune compromised with conditions such as AIDS or organ
transplantation.
Tissue cysts can range from 5 to 100 mm in size containing just
a few to thousands of encysted bradyzoites. Tissue cysts can be
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found in any organ, but are especially prevalent in the central
nervous system. The bradyzoites within the tissue cyst are covered
by a prominent translucent 0.25 to 0.75 mm thick cyst wall
structure (cyst wall) which can be visualized using electron micro-
scopy [6]. The cyst wall forms beneath a modified parasitophorous
vacuole membrane containing bradyzoites. The cyst wall is highly
glycosylated and stains easily with periodic acid-Schiff, Dolichos
biflorus lectin (DBA), and succinylated wheat germ agglutinin
[6–8]. These carbohydrate modifications of the cyst wall are
hypothesized to mask cyst wall proteins from host immune
responses and to provide structural and chemical resistance against
environmental stress, facilitating transmission of this pathogen [9].
The biogenesis, composition, and functions of the cyst wall
are not yet well defined. A cyst wall glycoprotein CST1 was
discovered more than a decade ago [10]. This protein, CST1,
binds to DBA lectin, suggesting that it is a glycoprotein that
contains N-acetyl-galactosamine. CST1 localized to the in vivo and
in vitro cyst wall, but was not found associated with the tachyzoite
parasitophorous vacuole. The corresponding gene, CST1, has not
previously been identified, as the available monoclonal antibody
73.18 [11] to CST1 recognizes a glycoepitope and attempts to
identify the glycoprotein recognized by this monoclonal antibody
were unsuccessful (Weiss LM, unpublished). While some progress
has occurred, cyst wall biology is still poorly understood despite
the clinical and biological importance of this structure for
transmission and latency in this important protozoan infection
[12]. We produced a new monoclonal antibody library to T. gondii
tissue cysts and used a combination of microscopic, genetic and
proteomic approaches to identify cyst wall components. Using this
approach we identified CST1, the gene corresponding to CST1,
and characterized the effect of a knockout of this gene on T. gondii.
Results
Monoclonal antibody SalmonE binds to the cyst wall
To identify cyst wall proteins, a hybridoma library was created
from mice immunized with a lysate of T. gondii ME49 cysts purified
from the brains of mice with chronic T. gondii infection. From
this library, we screened monoclonal antibodies by immunofluo-
rescence against ME49 T. gondii in vitro cysts (bradyzoite-) and
tachyzoite-containing vacuoles. Among the 189 cyst-wall positive
hybridomas, we identified an mAb clone SalmonE that reacted
with bradyzoite-containing parasitophorous vacuoles and uni-
formly stained the limiting parasitophorous vacuole membrane
of BAG1-positive parasites (bradyzoites) but did not stain vacuoles
containing BAG1 negative parasites (Figure 1A). BAG1 negative
vacuoles were positive for SAG1, a tachyzoite specific marker
Author Summary
Toxoplasma gondii causes severe encephalitis in immune
compromised hosts after reactivation of brain cysts that
persist for the life span of the host. The biological
mechanisms of bradyzoite persistence within cysts are
not fully understood. The glycosylated cyst wall is thought
to play a crucial role in survival of bradyzoites during
chronic infection as well as successful oral transmission of
infection. Here we have identified the gene encoding cyst
wall glycoprotein CST1. When we delete the CST1 gene,
parasites form dramatically fragile brain cysts. Parasites
lacking CST1 develop fewer brain cysts, show dysregula-
tion of bradyzoite-specific gene expression and are less
able to grow under stressed conditions. The rescue of
these phenotypes requires the heavily glycosylated mucin
domain of CST1. These studies demonstrate that the
glycosylation of CST1 plays a significant role in the
structural integrity and persistence of brain cysts. Agents
that perturb CST1 glycosylation have the potential to
disrupt formation of latent brain cysts, preventing chronic
Toxoplasma infection.
Figure 1. Monoclonal antibody SalmonE binds to the cyst wall of cysts isolated in vitro and in vivo. (A) Human foreskin fibroblasts (HFF)
were infected with ME49 strain of T. gondii under alkaline conditions (pH 8.1) for 3 days. Anti-BAG1 antibody (red) staining demonstrates that the
smaller parasitophorous vacuole on the right is an in vitro cyst; mAb SalmonE (green) binds to the parasitophorous vacuole of in vitro cyst, but not to
the larger parasitophorous vacuole containing tachyzoites on the left. Bar, 10 mm. (B) Immuno-electron microscopic labeling of the cyst wall with
mAb SalmonE. A ME49 brain tissue cyst isolated from an infected mouse was processed for immuno-electron microscopy and probed with mAb
SalmonE. The gold particles demonstrate that mAb SalmonE localizes to the granular layer (arrow) under the limiting membrane of cyst wall. Bar,
200 nm.
doi:10.1371/journal.ppat.1003823.g001
T. gondii Cyst Wall Protein CST1
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(data not shown). This candidate cyst wall reactive monoclonal
antibody was used to further characterize the cyst wall.
Since in vitro cysts do not completely differentiate, we examined
the localization of SalmonE in cysts isolated from mice with
chronic T. gondii infection. Within these more mature cysts there is
a more organized cyst wall structure, and the bradyzoites within
these cysts enter Go and arrest in the cell cycle [12,13]. T. gondii
(ME49 strain) in vivo brain cysts harvested from infected mice
were labeled with SalmonE and analyzed using immuno-electron
microscopy (Figure 1B). SalmonE recognizes the diffuse thick layer
of the cyst wall beneath the limiting membrane of the cyst wall in
a distribution similar to the reactivity of the mAb specific for
CST1 as well as the DBA lectin [10].
CST1, the mAb SalmonE reactive molecule, is a SRS
glycoprotein with an extended mucin domain
To determine the target of monoclonal antibody SalmonE,
antigens from ME49 in vitro derived bradyzoite lysates were
immunoprecipitated with mAb SalmonE, separated with SDS-
PAGE and the two major candidate protein bands (a low signal
intensity 150 kDa band and a high signal intensity high molecular
weight band in the stacking gel) were excised and analyzed by
MALDI-TOF mass spectrometry. The high molecular band
had two peptides that matched the predicted gene product of
TGME49_064660 (peptides: RGGGFLTTYTLNVPRL and
KEFLRPLADLVPGASLKL, MASCOT, p,1027, Figure 2A),
which had been annotated as SRS44 in a published analysis of SRS
domain-containing proteins [14]. The low molecular weight band
had two peptides that matched SRS13 (peptides: KLPEKPAAA-
VAR and LTLDAGPPQATTLCYK), a glycoprotein we also
subsequently characterized (Tomita and Weiss, in preparation).
Polyclonal murine antiserum raised to the first 200 amino acids of
SRS13 did not react with the cyst wall (data not shown). There was
no other protein identified from SalmonE immunoprecipitated
bands. To verify that the TGME49_064660 gene product is
responsible for the cyst wall staining of monoclonal antibody
SalmonE, mouse antiserum was raised against recombinant
TGME49_064660 protein consisting of the first 200 amino acid
of the predicted gene (Figure 2A, rTGME49_064660). Probing in
vitro cysts with the anti-rTGME49_064660 serum revealed a similar
pattern of staining as seen with the monoclonal antibody SalmonE
(Figure 1A and 2B). This verified that TGME49_064660 is indeed
a cyst wall gene. After completion of molecular verification (see
below for details) TGME49_064660 was identified as CST1, the
gene corresponding to the previously identified protein CST1 [10].
The cyst wall localization as well as its identification as an
SRS protein suggested that CST1 should be a secreted protein;
however, the current annotated TGME49_064660 gene product
in ToxoDB.org does not contain a potential signal peptide
sequence (SignalP 4.0 prediction [15]). Examination of the
upstream sequences (Figure S1A), suggested that the gene model
was incorrect. Use of 59 rapid amplification of cDNA ends (RACE)
demonstrated additional coding sequence, a revised 59 UTR
(Figure S1A) and also confirmed that CST1 (TGME49_064660)
does not extend into the predicted upstream gene TGME49
_064670. Sequence analysis of the 59 RACE product revealed an
in-frame methionine codon located 43 residues upstream of the
annotated predicted start site (Figure S1A). The protein predicted
using this upstream methionine codon encodes a high probability
signal peptide with a cleavage site; therefore, it is likely that CST1
translation begins at this methionine, 43 residues upstream of the
annotated initiator methionine codon.
CST1 contains thirteen SRS domains (Figure 2A) and is unique
among the SRS family proteins in having such a large number of
Figure 2. Monoclonal antibody SalmonE recognizes cyst wall protein CST1 (TGME49_064660). (A) The two peptides (red and blue bars)
identified by mass spectrometry were mapped to the TGME49_064660 (CST1) protein. The recombinant protein rTGME49_064660 is the first 200
amino acids of the predicted gene (green bar). (B) CST1 (TGME49_064660) antiserum stains in vitro cyst walls. HFF cells were infected with ME49
strain of T. gondii under alkaline conditions for 3 days. Anti-rTGME49_064660 antiserum (mice immunized with TGME49_064660 recombinant protein
green) stains the parasitophorous vacuole containing BAG1-positive parasites (red). Bar, 10 mm.
doi:10.1371/journal.ppat.1003823.g002
T. gondii Cyst Wall Protein CST1
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SRS domains. Another striking feature of the predicted protein is
the presence of a 263 amino acid stretch with multiple threonine-
rich tandem repeats of T5–11[R/I]K2P; this region has homology
to the mucin-like domains in a major glycoprotein of Cryptospo-
ridium parvum (GP900, CMU_014140) (Figure 2A). Since mucin
domains are typically extensively O-glycosylated on Ser or Thr
residues, the probability of O-glycosylation at this mucin domain
was assessed using neural network model NetOGlyc 3.1 [16]. Of
the 157 threonines in the mucin domain, 95% were predicted to
be O-glycosylated using NetOGlyc 3.1(Figure 3A).
To investigate whether the CST1 is O-glycosylated, SalmonE-
immunoprecipitates were probed with Dolichos biflorus lectin (DBA),
a marker for the cyst wall that recognizes GalNAc [17] (Figure 3B).
DBA lectin overlays verified that CST1, the TGME49_064660
gene product, is a glycoprotein. CST1 mRNA is expressed in type I
(RH), type II (P/ME49) and type III (CTG) strains as evidenced
by expression data from www.ToxoDB.org and our RNA-seq data
(Figure S1).
CST1 is not required for cyst formation
To understand the function of CST1 we deleted the entire
CST1 gene (Figure 4A) in the PruDku80 background [18]. This
strain has a high frequency of homologous recombination that
facilitates the development of knock-outs and also contains GFP
under the control of bradyzoite specific LDH2 promoter so that
the brain cysts containing bradyzoites can readily be identified
Figure 3. The mucin domain of CST1 is highly O-glycosylated. (A) The glycosylation potential of CST1 was predicted by the NetOGlyc 3.1. Red
line indicates the threshold and blue line indicates the potential at each S/T amino acid position with domain-scheme overlay. This method predicts
that the mucin domain is likely to be highly O-glycosylated. (B) mAb SalmonE immunoprecipitates are bound by DBA lectin. The left lane is 10 ml of
whole parasite lysate (ME49 at pH 8.1) and the right lane is the sample (equivalent to 200 ml lysate) that was immunoprecipitated with mAb SalmonE,
separated by SDS-PAGE and transferred to nitrocellulose membrane. The membrane was probed with AP-conjugated DBA lectin.
doi:10.1371/journal.ppat.1003823.g003
T. gondii Cyst Wall Protein CST1
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by fluorescence microscopy [18]. The deletion of the CST1 (Dcst1
T. gondii strain) was verified by PCR (Figure S1B) as well as by
RNA-seq (Figure S1C).
T. gondii lysates of parasites grown in vitro at pH 8.1
(bradyzoites) and pH 7 (tachyzoites) were probed with mAb
SalmonE by immunoblot (Figure 4B). The mAb SalmonE reactive
band at pH 8.1 is seen in the stacking gel, suggesting that this is a
high molecular mass antigen with extensive post translational
glycosylation that may prevent entry into the resolving gel. While
the mAb SalmonE reactivity is virtually absent in parasites grown
at pH 7, a strong signal was observed in lysates from wild-type
parasites grown at pH 8.1. These CST1 bands also bind to DBA
Figure 4. Characterization of CST1 knock out (Dcst1) and CST1 complemented T. gondii strains. (A) Schematic representation of
disruption of CST1 and complementation of Dcst1 mutant. Upper half of the diagram represents the deletion of whole CST1 gene with Dcst1 vector.
Lower half represents the complementation of CST1 genes at UPRT locus. (B) Immunoblot of T. gondii parasite cultures grown in normal and alkaline
conditions probed with mAb SalmonE. SalmonE reactive antigen (CST1) is induced in alkaline conditions. Dcst1 knockout parasites are not recognized
by mAb Salmon E, but reactivity is restored in full-length complement (Dcst1::cst1) but CST1Dmuc protein lacks the reactivity due to the loss of mucin-
like domain. The parasite specific dense granule protein GRA1 is used as a loading control. (C) CST1 and DBA co-localize on in vitro cyst wall. HFF cells
infected with WT, Dcst1, Dcst1::cst1, or Dcst1::cst1Dmuc T. gondii strains under alkaline conditions were probed with SalmonE (red) or DBA lectin
(green). Monoclonal antibody SalmonE and DBA staining co-localized. The presence of the full-length CST1 gene is necessary for mAb SalmonE and
DBA staining on cyst wall. Bar, 10 mm.
doi:10.1371/journal.ppat.1003823.g004
T. gondii Cyst Wall Protein CST1
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lectin consistent with the presence of glycosylation in this protein
(Figure S2).
Since CST1 was originally defined by reactivity to DBA
and recognition by mAb 73.18 [10,11], the CST1 deficient strain
(Dcst1) should not be recognized by mAb 73.18. Immunopurified
CST1, and cell lysates from pH 8.1 treated T. gondii Pru wild
type or Dcst1 cultures were probed with the previously described
CST1 specific mAb 73.18 and mAb SalmonE (Figure 5A).
Monoclonal antibody SalmonE and mAb 73.18 had similar
patterns of reactivity on immunoblot, and, as expected, the Dcst1
did not have the major immunoreactive band and had lost the
characteristic cyst wall labeling seen with DBA, mAb SalmonE
(Figure 4C), or mAb 73.18 (Figure 5B). These cysts that did not
stain with DBA, mAb SalmonE or 73.18 were still positive with
Figure 5. SalmonE and mAb 73.18 recognize CST1 (TGME49_064660). (A) Immunoblot of mAb SalmonE immunoprecipitated material
(ME49), WT lysate (Pru) and Dcst1 lysate probed with mAb SalmonE (green) and mAb 73.18 (red). This immunoblot demonstrated that mAb SalmonE
and mAb 73.18 bind to the same major species which is not detectable in Dcst1 parasites. (B) IFA of in vitro cysts probed with CST1 specific
monoclonal antibody 73.18 (red) and DBA lectin (green). The presence of full-length CST1 is required for both mAb 73.18 and DBA cyst wall staining.
Bar, 10 mm.
doi:10.1371/journal.ppat.1003823.g005
T. gondii Cyst Wall Protein CST1
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BAG1 antibody (Figure 6). Examination of brains of mice infected
with Dcst1 T. gondii demonstrated that cyst formation could still
occur in this knockout strain (Fig. 7).
Collectively, these results indicate CST1 is not required for
bradyzoite or cyst formation and that CST1 is the cyst wall protein
recognized by mAb SalmonE, DBA, and mAb 73.18. Both DBA
and mAb 73.18 recognize glycoepitopes, and we noted that while
cyst wall reactivity was lost in Dcst1, there was some residual
reactivity seen within the parasites by mAb SalmonE, DBA and
mAb 73.18, suggesting that other less abundant glycoepitopes that
Figure 6. BAG1 expression in WT, Dcst1, Dcst1::cst and Dcst1::cst1Dmuc parasites. HFF cells were infected with either WT, Dcst1, Dcst1::cst and
Dcst1::cst1Dmuc parasites and probed with anti-CST1 antiserum (red) and rabbit anti-BAG1 (green). This demonstrates that differentiation occurs in the
Dcst1 and Dcst1::cst1Dmuc parasites.
doi:10.1371/journal.ppat.1003823.g006
Figure 7. Brain cyst burden and survival rate of infected mice at 4 weeks post infection. (A) Survival curve of the mice challenged with the
WT and mutant parasites (n = 20). (B) Brain cyst count of C57/BL6 mice infected with either WT, Dcst1, Dcst1:cst1 or Dcst1:cst1Dmuc parasites sacrificed
at 4 weeks post infection. The bars represent mean and standard deviation (n = 12). *p,0.05 (Mann-Whitney U test). (C) Immunohistochemistry of
brain sections from infected mice probed with anti-GFP antibody demonstrates the formation of brain cysts in vivo. Pru parasites are stably
transfected with LDH2-GFP enabling identification of bradyzoites within cysts. Bar, 10 mm.
doi:10.1371/journal.ppat.1003823.g007
T. gondii Cyst Wall Protein CST1
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react with mAb SalmonE, DBA, and mAb 73.18 are present in
bradyzoites.
Complementation of Dcst1 strain reveals that the mucin
domain is required for DBA lectin reactivity
To examine the role of glycosylation in CST1 function,
we complemented the Dcst1 strain with two variants of CST1
(Figure 4A). One Dcst1 line was complemented with a full-length
cDNA (Dcst1::cst1) and the other with a CST1 lacking the 789 bp
region coding for the mucin domain (Dcst1::cst1Dmuc). Following
transfection and selection, the presence of those complemented
genes were verified by PCR (Figure S1B) and RNA-seq (Figure
S1C). Stage specific expression of CST1 was equivalent to that
seen in the wild type parasite in the complemented Dcst1::cst1
T. gondii strain as verified by immunoblot with mAb SalmonE
(Figure 4B). IFA of pH 8.1 treated Dcst1::cst1 in vitro cysts
demonstrated that the strain complemented with full-length
cDNA of CST1 has the correct localization of CST1 to the cyst
wall, as well as the restoration of DBA staining (Figure 4C) and
mAb 73.18 staining (Figure 5B) of the cyst wall. These cysts
remained IFA positive for BAG1 (Figure 6).
In contrast, the Dcst1::cst1Dmuc parasites lack the major mAb
SalmonE and DBA reactive band in immunoblot (Figure 4B
and S2), and lack cyst wall staining with DBA, mAb SalmonE, and
mAb 73.18 in IFA (Figure 4C and 5B). The expression and
localization of CST1Dmuc protein was verified with a polyclonal
antibody produced against recombinant CST1 (rTGME49_
064660 AA1-200) (Figure S3).
Dcst1 parasites form fewer brain cysts and exhibit a
fragile cyst wall phenotype
To determine the effect of CST1 deletion or mucin domain
deletion in vivo, C57BL/6 mice were infected with wild type, Dcst1,
Dcst1::cst1, and Dcst1::cst1Dmuc parasites at 200 parasites per mouse.
The mouse survival rates (Figure 7A) during acute infection with
each parasite line were not statistically different (n = 20, Log-rank
test). The number of brain cysts per mouse at 4 weeks after
infection (Figure 7B) was reduced by 41% in the Dcst1 strain
(p,0.05, Mann-Whitney U test). Complementation with full
length (Dcst1::cst1), but not mucin-null (Dcst1::cst1Dmuc), restored the
cyst number level back to the wild type levels. Histological analysis
of the brains suggested that inflammation was less severe in D cst1
than the wild type (Figure S4); however this did not achieve
statistical significance. Cysts were produced in vivo by all mutants
(Figure 7C) and there was no difference in the size of cysts
produced by these mutants. Brains from mice infected with the
wild type, D cst1, D cst1::cst1Dmuc, and Dcst1::cst1 parasites were fed
to Balb/cDM1 and all were capable of transmitting infection.
During the brain cyst isolation procedure, cysts are subjected to
mechanical stress to release them from brain tissue to purify them
by isopycnic centrifugation [19]. The wild type cysts stayed intact
during this procedure, but Dcst1 brain cysts were much more
fragile and broke apart when homogenized using a pestle tissue
homogenizer to purify cysts from brain samples [19] (Figure 8A).
Despite many attempts, we were unable to develop a reliable
procedure to purify intact Dcst1 cysts from mouse brains or a
method to standardize cyst inocula to compare the transmissibility
of cysts from our mutant strains.
To further investigate the fragile phenotype, we examined
the ultrastructure of the brain cysts by electron microscopy.
Figure 8B demonstrates a wild type brain cyst, which has the
classic organized cyst wall with an underlying amorphous granular
layer. In contrast, the Dcst1 brain cysts lack this organization and
displayed a disrupted layer. Independently isolated Dcst1 clones
had the same fragile phenotype. Full length cDNA complemen-
tation of Dcst1 (Dcst1::cst1) rescued the fragile brain cyst phenotype
as well as restoring the cyst wall layer as seen by TEM (Figure 8).
In contrast, complementation of Dcst1 parasite with cst1Dmuc gene
did not rescue the fragile cyst wall phenotype or correct the
disruption of cyst wall layer seen by TEM (Figure 8). Measure-
ments of the cyst wall confirmed a significant decrease in the
cyst wall thickness with disruption of cst1: WT 153628 nm,
Dcst1 24610 nm, Dcst1::cst1 284665 nm, and D cst1::cst1Dmuc,
34614 nm (p,0.05 WT vs Dcst1, WT vs D cst1::cst1Dmuc) as well as
an increase in cyst wall thickness in the Dcst1::cst1 strain (p,0.05
WT vs D cst1::cst1).
To determine if cyst wall thickness affected cyst fragility, we
compared cyst fragility in individual brains using a relatively
vigorous disruption method with a small sintered glass pestle tissue
homogenizer (size A: 0.1–0.15 mm clearance, frosted inner glass
surface) that disrupts a significant fraction of wild-type cysts in
brain homogenate. For this experiment, brains (n = 4 per group)
were cut in half, the cysts in the right half were homogenized
unfixed, and the left half was fixed with 4% paraformaldehyde
overnight at 4uC prior to homogenization with the pestle
tissue homogenizer. Using this procedure 10060% of Dcst1 and
10060% Dcst1::cst1Dmuc cysts were broken. Interestingly, fewer
Dcst1::cst1 (1563%) cysts were broken than wild type cysts
(6168%), suggesting that the increased thickness of the cyst wall
seen on TEM (Figure 8) with Dcst1::cst1 parasites does protect the
cysts/bradyzoites from mechanical stress.
Dcst1 parasites replicate slower during in vitro bradyzoite
development
To examine any growth defects of the Dcst1 parasite, parasite
growth was measured with incorporation of 3H-uracil in pH 7.1
(tachyzoite stage) and pH 8.1 (bradyzoite differentiation) medium.
The deletion of CST1 resulted in a reduction in the growth rate
at pH 8.1 of the Dcst1 parasite compared to the growth rate of
the wild type (WT) parasites (Figure 9A, p,0.005), this reduction
in growth was not seen at pH 7 (Figure S5). This slower growth
phenotype seen with bradyzoite inducing condition in Dcst1
parasites was rescued by full length CST1 complementation, but
only partially by the mucin-null CST1 (Figure 9B).
The Dcst1 strain has dysregulated expression of
bradyzoite and pH-induced genes
Since there was reduction in growth rate at pH 8.1 in vitro for
the Dcst1 parasite and fewer brain cysts in vivo, we investigated
whether the cst1 mutants might have global changes in gene
expression under the bradyzoite-inducing conditions. The tran-
scriptome of parasites cultured at pH 7 (tachyzoite) was compared
with the transcriptome of parasites cultured at pH 8.1 (bradyzoite)
for 3 days using RNA-seq. Figure 10A shows the heat map of top
50 upregulated genes at bradyzoite conditions in wild type (WT) T.
gondii (see Table S1 for a complete list of these genes). Expression
of 49 of 50 genes was less efficiently induced by pH shock in the
Dcst1 strain compared to control WT parasites. The complemen-
tation of full-length CST1 (Dcst1::cst1) restored the majority of
these genes back to their wild type level. However, the mucin-null
complement (Dcst1::cst1Dmuc) was not able to restore expression of
these genes to wild type levels. Figure 10B shows the fold change in
gene expression for several known bradyzoite specific genes. These
bradyzoite genes also follow a similar pattern of reduced gene
upregulation with Dcst1, restoration with Dcst1::cst1 and only a
partial restoration with Dcst1::cst1Dmuc. The altered gene expression
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Figure 8. The mucin domain of CST1 is required to form mechanical stress-resistant cyst wall structures. (A) Brain cysts of WT and
mutants after gentle brain homogenization, observed under epifluorescence microscopy. Bar, 10 mm. (B) Electron micrograph of T. gondii brain cysts
demonstrates an alteration in the cyst wall with disruption and loss of the granular layer found underneath the cyst wall membrane. This disruption is
visible in the Dcst1 and Dcst1::cst1Dmuc cysts, but no disruption is seen in the WT and Dcst1::cst1 cysts. Red arrows indicate the cyst wall membrane
and the blue arrows indicate the cyst wall granular layer. Measurements of the cyst wall: WT 153628 nm, Dcst1 24610 nm, Dcst1::cst1 284665 nm,
and D cst1::cst1Dmuc 34614 nm (p,0.05 WT vs Dcst1, WT vs D cst1::cst1Dmuc, and WT vs D cst1::cst1). The original image magnification was 20,0006on
all of these EM images. Bar, 200 nm.
doi:10.1371/journal.ppat.1003823.g008
Figure 9. Growth of Dcst1 parasite is impaired at pH 8.1 but not at pH 7.1. (A) Growth of WT (blue) or Dcst1 parasites (red) in HFF cells at
pH 8.1 were measured as 3H-uracil incorporation into parasites DNA. Mean and standard deviation are shown. n = 3, * p,0.005. This experiment was
repeated 3 times with similar results. (B) Number of parasites inside vacuoles in HFF cells at pH 8.1 per 600 host cells. 3H-uracil incorporation was not
done due to the lack of UPRT gene in complement strains.
doi:10.1371/journal.ppat.1003823.g009
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pattern was not evident for housekeeping or tachyzoite specific
genes. This RNA-seq data suggests that lack of CST1 disrupts
bradyzoite differentiation, but not enough to prevent in vitro and in
vivo cyst formation.
Discussion
This study identifies the gene encoding the major cyst wall
DBA-binding protein CST1. CST1 is a SRS containing protein
with an extended mucin domain. The mucin domain of CST1
is necessary for DBA binding and is a major domain for
glycosylation of this protein. Dcst1 parasites can differentiate and
form mouse brain cysts without CST1; however, CST1 and CST1
glycosylation is required for formation of an organized cyst wall
layer that confers structural rigidity to the cyst wall. This is the first
cyst wall protein that has been shown to be essential to establish
the physical integrity of in vivo brain cysts. Complementation
demonstrates that the mucin domain of CST1 is necessary for
the cyst wall organization and rigidity. In addition to its role in
structural stability of the cyst wall, a lack of CST1 also reduces in
vitro growth rate, mouse brain cyst number, and pH 8-induced
bradyzoite specific gene upregulation in T. gondii. These results
suggest that expression of CST1 or glycosylation of CST1 in early
cyst development influences the expression pattern of genes during
bradyzoite differentiation.
Previous work has suggested that the cyst wall contains several
glycoproteins including CST1 [10], a proteophosphoglycan [11]
and other unknown glycoproteins reacting with s-WGA [8]. CST1
is highly unusual SRS protein in that it has a large mucin domain
and thirteen SRS domains. The glycoprotein gp900, from another
Apicomplexan parasite Cryptosporidium parvum, has a large mucin-
like domain that has 68% sequence similarity with the mucin
domain of CST1. Other than the presence of mucin-like domain,
there is no sequence similarity between these two glycoproteins.
The C. parvum gp900 has a transmembrane domain, is expressed
on the plasma membrane, and is shed into the environment [20].
The gp900 protein is localized to the tethers on the inner surface
of oocyst walls [20,21]. This suggests that gp900, a large mucin-
like protein, is important for making a structurally rigid enclosure
for this parasite. Other smaller glycoproteins (gp40 and gp15) are
present in the oocyst wall tethers of C. parvum [20,21]. Our studies
with CST1 in T. gondii tissue cysts suggest phylogenetic conser-
vation of the functions of these secreted structural glycoproteins in
the Apicomplexa.
The protozoan parasite Trypanosoma cruzi has up to 850 highly
glycosylated and GPI-anchored surface mucin genes that form
a stage specific mosaic coat on their cell surface. It is suggested
that these glycoproteins have a protective role against the
proteases in the intestine of the insect vector [22], function
in attachment to the host cell, and as an immune evasion
mechanism [23]. CST1, which has large mucin domain and a
predicted GPI-anchor (as with other SRS domain containing
proteins), may have comparable functions in terms of protecting
bradyzoites in the cyst from the proteases present in the gas-
trointestinal tract during the oral infection or in the surrounding
necrotic tissues when the host dies [22]. The ability of mucins to
retain large amount of water probably protects parasites by
preventing dehydration, facilitating parasite transmission to the
next host.
Of the 189 cyst-wall positive hybridomas we identified, 34 had
an identical immunoblot pattern as mAb SalmonE. This suggests
that CST1 may be highly immunogenic toward the Th2 pathway.
Cysts are present not only in the central nervous system, but also
in the visceral organs and muscles. CST1 from ruptured cysts can
induce a strong antibody response and this may facilitate the
clearance of cysts by the immune system when their host cells are
dead. Cloned hybridomas specific to CST1 included other classes
of antibodies (e.g. IgG2b and IgM), therefore, CST1 does not only
elicit the production of IgE antibody.
Figure 10. Lack of CST1 reduces bradyzoite gene expression.
(A) Heat map of fold change in gene expression (pH 8/pH 7) of wild
type and cst1 mutants. The top 50 upregulated genes in wild type T.
gondii are displayed in order. The number is the gene name in TGME49
(ToxoDB ver 6.1). Gene upregulation is reduced in the Dcst1 strain. The
full length complement strain Dcst1:cst1 has a restoration of gene
upregulation to control (WT) levels, but the mucin-null complement
strain Dcst1:cst1Dmuc did not have restoration of these gene levels. (B)
Upregulation of known bradyzoite specific gene expressions shows the
same pattern. Note that the housekeeping and tachyzoite specific
genes did not follow the same expression pattern. Both (A) and (B)
graphs were generated from the same RNA-seq data set.
doi:10.1371/journal.ppat.1003823.g010
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In a previous study, CST1 was detected by its reactivity to the
mAb 73.18 in the R5 strain of T. gondii, an atovoquone resistant
mutant that spontaneously formed cysts more readily [24]. In this
strain CST1 was reported as a 116 kDa band on 2D SDS-PAGE
[10]. In our current study, both mAb SalmonE and mAb 73.18
detected two distinct bands (Figures 5A, S6), one migrating at
150 kDa (SRS13, Weiss, unpublished data) and one band (CST1)
in the stacking gel (.210 kDa). Similar immunoblot patterns were
seen using Pru, ME49 or the ME49 mutant R5 (Figure S6). Both
bands also react with DBA lectin indicating that the SRS13 has
similar glycoepitope as CST1. This SRS13 reactivity is still present
in the Dcst1 strain and does not localize to cyst wall (Tomita and
Weiss, unpublished data) and mAb SalmonE staining of the
150 kDa band is absent in a Dsrs13 strain (Figure S6). Monoclonal
antibody SalmonE, mAb 73.18, and DBA all display no cyst wall
staining in the Dcst1 strain, consistent with SRS44 being CST1, a
major cyst wall glycoprotein identified by our laboratory over 15
years ago [10,11]. During previous studies we were not able to
detect the band in the stacking gel since the stacking gel was
separated from the resolving gel before the transfer to a
membrane. The discrepancy in the molecular-weight of 116 kDa
and 150 kDa may be due to the difference in gel conditions or
molecular markers.
CST1 is one of several cyst wall proteins that are induced during
bradyzoite development. Recently, a screening of insertional
mutants for a reduction of in vitro cyst development led to the
identification of another T. gondii cyst wall protein, proteopho-
sphoglycan (TgPPG) [25]. TgPPG is expressed in the cyst wall and
is probably highly glycosylated, as evidenced by its retention in
the stacking gel on SDS-PAGE. Disruption of TgPPG gene results
in the delay in cyst wall formation and bradyzoite conversion;
however, complementation only rescued cyst wall formation
measured by the DBA staining, but not bradyzoite differentiation
as measured by BAG1 expression. In another recent study,
transcriptomic analysis of brain cysts yielded two distinct cyst
wall proteins Bradyzoite Pseudokinase 1 (BPK1) and Microneme
Adhesive Repeat domain-containing protein 4 (MCP4) [13].
Subsequent study demonstrated that BPK1 plays a role in effective
oral transmission [26]. Finally, several GRA proteins have been
demonstrated to localize the cyst wall in bradyzoite parasitophor-
ous vacuoles, as well as to the dense granules in both tachyzoites
and bradyzoties [27]. Deletion of cyst wall associated GRA6 was
shown to dramatically decrease tissue cyst burdens in mice [18].
The biological functions of these cyst wall proteins await further
study.
Toxoplasma gondii is one of the most successful parasites partly
because it forms persistent latent cysts that last for the life of
its hosts, and the cyst wall is a critical biological structure for
this persistence. CST1 functions as a key structural component
reinforcing the cyst wall structure and conferring resistance to
physical stress to the T. gondii cyst. The fragile cyst phenotype in
the Dcst1 strain suggests that transmission and persistence could be
affected by this gene deletion, but this hypothesis could not be fully
tested, as intact viable cysts cannot be purified from mouse brains
to perform quantitative oral challenge experiments [10,11].
There are 5 putative UDP:GalNAc:polypeptide N-acetylgalac-
tosaminyltransferases (ppGalNAc-T) in the T. gondii genome
(Toxo DB). Two of these, T1 and T3, were expressed in insect
cells and their glycosyl transferase activity was confirmed [28].
Both transferases turned out to be ‘‘follow-up’’ transferases, only
transfering to the pre-O-glycosylated peptide. At this point, it is
not known which glycosyl transferasase is responsible for the heavy
glycosylation of CST1 mucin domain. A recent study showed that
the nucleotide sugar transporter (TgNST1) is necessary for the
glycosylation of cyst wall proteins such as CST1 [29]. Deletion of
TgNST1 resulted in fewer brain cysts and the authors concluded
that glycosylation of the cyst wall is required for persistence of
bradyzoites, but did not identify which glycoproteins were most
critical. Our studies show a similar phenotype for parasites lacking
CST1, consistent with CST1 being the major cyst wall glycopro-
tein involved in the maintenance of brain cyst burden. Further-
more, parasites expressing a mutant CST1 lacking the mucin
domain have a similar defect, demonstrating that post translational
glycosylation of the CST1 mucin domain is critical for CST1
biological function. Therefore enzymes involved in glycosylation
of cyst wall proteins including candidate enzymes such as T. gondii
ppGalNAc-Ts have potential as therapeutic agents to prevent T.
gondii bradyzoite persistence.
Materials and Methods
T.gondii cell culture and strains
Human foreskin fibroblasts (HFF) were maintained in 10%
fetal bovine serum pH 7 DMEM with penicillin-streptomycin at
5% CO2. Confluent monolayers were infected with Type II strains
ME49, the reference genome strain, or PruDku80 strain of T.
gondii, which is widely used for genetic studies [18]. For in vitro
bradyzoite differentiation, parasite strains were grown in differen-
tiation medium (DMEM medium adjusted to pH 8.1 with 10 mM
HEPES and 1% fetal bovine serum with penicillin-streptomycin)
for 3 days at 0.5% CO2.
Ethics statement
All animal experiments were conducted according to the
U.S.A. Public Health Service Policy on Humane Care and
Use of Laboratory Animals. Animals were maintained in an
AAALAC-approved facility and all protocols were approved by
the Institutional Care Committee of the Albert Einstein College
of Medicine, Bronx, New York(Animal Protocols 20121104,
20121109 and 20121110; Animal Welfare Assurance number
A3312-01).
No human samples were used in these experiments. Human
foreskin fibroblasts were obtained from ATCC.
Monoclonal antibody production
BALB/cdm1 mice, which have a deletion in the Ld gene at
the HLA-2L locus and produce more brain cysts than wild
type BALB/c [30], were infected with ME49 strain of T. gondii
and treated with sulfamerazine at 30 mg/L in drinking water to
minimize death from the acute infection. Four weeks after the
infection, brain cysts were isolated using previously described
isopycnic centrifugation [19]. Briefly, brains were isolated and
homogenized in PBS with a pestle tissue homogenizer with
clearance of 0.15–0.23 mm (Thomas Scientific) for 10 times.
Percoll was added to 40% of the total volume and centrifuged at
27,0006g for 20 minutes. The middle layer was recovered and
centrifuged with equal volume of PBS at 1006g for 10 minutes.
Cysts were then subjected to ten freeze-thaw cycles, (3 minutes
each: 100% ethanol-dry ice bath followed by room temperature
water bath) and emulsified with an equal volume of Freund’s
complete adjuvant. The emulsion was injected into BALB/c mice
subcutaneously. Two months later, spleens were isolated from
the immunized mice and fused with myeloma cell line to create
hybridoma libraries. Using the IFA, ELISA and immunoblot,
those hybridoma supernatants were screened against parasites that
were cultured in pH 8.1 medium. IFA patterns were similar for
two Type II strains ME49 and Pru. Subcloned hybridoma cells
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were cultured in CELLine bioreactor (Integra) for large-scale
production of monoclonal antibodies.
Transmission electron microscopy
The BALB/cdm1 mice were infected with Pru strain of T. gondii
for 4 weeks in the presence of sulfamerazine at 30 mg/L
in drinking water. After they were harvested, whole brains were
fixed in 4% paraformaldehyde in PBS for overnight, followed by
homogenization and isopycnic centrifugation as described above.
While wild-type cysts did not require fixation prior to processing,
fixation of Dcst1 infected brains was necessary in order to prevent
breakage of fragile brain cysts. The isolated cysts were fixed with
2.5% glutaraldehyde, 2% paraformaldehyde in 0.1M sodium
cacodylate buffer, postfixed with 1% osmium tetroxide followed by
2% uranyl acetate, dehydrated through a graded series of ethanol
and embedded in LX112 resin (LADD Research Industries,
Burlington VT). Ultrathin sections were cut on a Reichert
Ultracut UCT, stained with uranyl acetate followed by lead
citrate and viewed on a JOEL 1200EX transmission electron
microscope at 80 kv.
For immunoelectron microscopy, the cysts were fixed with 4%
paraformaldehyde 0.05% glutaraldehyde in 0.1M sodium caco-
dylate buffer, dehydrated through a graded series of ethanol, with
a progressive lowering of the temperature to 250uC in a Leica
EMAFS, embedded in Lowicryl HM-20 monostep resin (Electron
Microscopy Sciences), and polymerized using UV light. Ultrathin
sections were cut on a Reichert Ultracut E, immunolabeled
with SalmonE, and then stained with uranyl acetate followed by
lead citrate. Stained sections were viewed on a JOEL 1200EX
transmission electron microscope at 80 kv.
Identification of the SalmonE reactive glycoprotein by
mass spectrometry
SalmonE was crosslinked to the Protein L agarose beads with
disuccinimidyl suberate following the manufacturer’s protocol
(Thermo Scientific). Human foreskin fibroblasts were infected with
ME49 strain of T. gondii and incubated for 3 days in pH 8.1
medium with 10% FBS at 0.5% CO2. Cells were lysed with 1%
TritonX-100 in PBS with proteinase inhibitor cocktail and
incubated with SalmonE-beads for 2 hours at 4uC. The beads
were extensively washed with 1% TritonX-100 PBS and eluted
with 0.1M glycine at pH 2.5. The eluate was neutralized and
separated on SDS-PAGE. The gel was stained with Coomassie
Brilliant Blue and a visible high molecular-weight band was
excised. The protein in the band was reduced and alkylated using
TCEP and iodoacetamide then digested with trypsin in 25 mM
ammonium bicarbonate/0.01% ProteaseMax at 50uC for 1 hour.
The resulting digest was cleaned with C18 ziptip and the peptides
eluted onto a MALDI plate with a saturated solution of a-
cyanohydroxycinnamic acid in 70% acetonitrile/0.1% trifluoroa-
cetic acid. MS/MS analysis of the digested sample was carried out
using the AB Sciex 4800 MALDI-TOF-TOF (Applied Biosystems),
operated at 20 kV accelerating voltage in the reflector positive ion
mode. The MS/MS data generated were converted to mgf files and
searched against EPICDB [31] using the in-house Mascot Protein
Search engine (Matrix Science) for protein identification.
Production of CST1 mouse antisera
RNA was isolated from ME49 strain of T. gondii and a cDNA
library was created using SuperScript III First Strand Kit
(Invitrogen). The first 200 peptides of the CST1 (TGME49_
064660), as predicted in ToxoDB (i.e. this does not include
the probable N-terminal extension of CST1 gene predicted using
SignalP 4.0 [15]), was amplified by PCR, cloned into the pET32
vector and used to transform BL21 competent E. coli. Recom-
binant CST1 protein was expressed using Overnight Express
Autoinduction System 1 (Novagen), purified with nickel column,
and separated on SDS-PAGE. The band was cut out and
emulsified with Freund’s complete adjuvant and immunized into
BALB/c mice intraperitoneally. Three months after the immuni-
zation, antisera were collected and probed against in vitro cysts
using IFA.
CST1 (TGME49_064660; SRS44) knock-out
Type II Prugniaud strain with deletion of the Ku80 gene
(PruDku80) [18] was used as the background strain for the creation
of Dcst1 strain. The construct for the knockout was built as
previously described [18]. Briefly, 1 kb upstream and downstream
genomic DNA sequence of TGME_064660 gene were amplified
from the parental PruDku80 strain. These fragments were
concatenated into pRS416 yeast shuttle vector (ATCC) flanking
the selectable marker hypoxanthine-xanthine-guanine phosphor-
ibosyltransferase [HXGPRT] cassette using the yeast strain
ATCC#90845. This construct deletes whole CST1 gene as well
as 205 nucleotides 59 upstream region from the predicted start site.
This 59 region includes the probable start site and signal peptides.
All the primers used in the plasmid construct are listed in the
Supplemental material (Table S2). The parasites were transfected
with the linearized Dcst1 vector and subcloned in the presence of
25 mg/ml mycophenolic acid and 50 mg/ml xanthine. Integration
of Dcst1 vector at the TGME49_064660 locus was verified by
PCR. Lack of CST1 protein expression was confirmed with IFA
and immunoblot.
Complementation of CST1
For CST1 complementation, DNA fragments were concatenat-
ed into pSMART-BAC plasmid (Lucigen) using In-Fusion system
(Clontech) following the manufacture’s protocol. The homologous
sequences 1 kb upstream and downstream of UPRT coding region
for the UPRT locus were isolated from genomic DNA. Flanking
sequences 1.3 kb 59 and 39 of CST1 were isolated from Pru
genomic DNA. TGME49_064660 cDNA was generated from
RNA harvested from Pru strain cultured at pH 8.1. The fragments
were concatenated in the following order, 59 UPRT recombina-
tion sequence, TGME49_064660 upstream element, TGME49_
064660 cDNA, TGME49_064660 39 UTR, and 39 UPRT
recombination sequence.
For the mucin domain null mutant complementation, two
fragments (base 1–6006 and 6766–7035 with appropriate adapt-
ers) were used instead of whole cDNA. This mucin domain null
vector replaces the mucin domain (nt 6007–6765) with a 1xFLAG
sequence. The parasites were transfected with complementation
vectors and subcloned in the presence of 5 mM 5-fluorodeoxyur-
idine (FUDR). Integration of complementing vectors at the UPRT
locus was verified with PCR.
Our attempts to use the HXGPRT selectable marker present in
the Dcst1 parasite to complement the endogenous cst1 locus were
not successful. This was probably due to the low level expression of
HXGPRT at the cst1 locus that was not sufficient for negative
selection using 6-thioxanthine, but was sufficient for positive
selection in constructing the knockout using mycophenolic acid
(MPA). We have experienced similar problems using the Dku80
system with the HGXPRT selectable marker and have found that
removal of this marker by negative selection is not feasible at all
loci and needs to be evaluated for each knock-out. Therefore
complementation was performed at the UPRT locus for the cst1
gene since this target provides a direct selection and the loss of
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UPRT does not influence cyst development or cyst burdens in
mice [18].
59 RACE
RNA was isolated using RNeasy mini with DNase treatment
from HFF infected with ME49 strain of T. gondii culture in
pH 8.1 medium for 3 days. 59 UTR was amplified with
FirstChoice RLM-RACE kit (Ambion) with gene specific primer
GGGCGGGTCGAAAATGTTG following the manufacturer’s
protocol. The DNA was sequenced with ABI 3730 DNA analyzer.
Immunofluorescence assay
Cells were fixed with 4% paraformaldehyde in PBS for
30 minutes on ice and then permeablized with 0.2% Tri-
tonX100/0.1% glycine/0.2% bovine serum albumin (BSA) in
PBS on ice for 20 minutes. The cells were washed with 0.2%
BSA in PBS three times and blocked with 1% BSA in PBS at
4uC overnight. All incubation with primary and secondary
antibodies was done at 37uC for 90 minutes in a moist chamber.
Concentration of the antibodies and probes used were 20 mg/ml
for FITC-conjugated DBA (Vector Lab), 1:50 for antibody 73.18,
1:100 for SalmonE, 1:25 for mouse polyclonal anti-CST1(1–200),
1:50 for rabbit anti-BAG, 1:200 anti-FLAG M2 (Sigma) all in 1%
BSA/PBS. Cells were washed three times with 0.2% BSA/PBS
then incubated with appropriate secondary antibody at 1:500.
After incubation, the cells were washed three times with 0.2%
BSA/PBS and mounted with ProLong Gold antifade (Invitrogen).
Photomicrographs were taken either with a SP5 confocal
microscope (Leica) or Microphoto-FXA epifluorescence micro-
scope (Nikon).
Immunoblotting
HFF cells were infected with T. gondii in normal DMEM
medium or differentiation medium and kept in 5% or 0.5% CO2
respectively. Cells were harvested at 3 dpi with cell scraper,
centrifuged at 30006g for 15 minutes and lysed with 1%
TritonX100, 1% SDS, protease inhibitor cocktail in PBS.
The samples were resolved in 10% SDS-PAGE at 100 V and
transferred at 250 mA for 90 minutes on the PVDF membrane
Immobilon-FL (Millipore). The membrane was blocked overnight
with 5% non-fat dry milk (NFDM) in PBST, then probed with
SalmonE at 1:250 and anti-GRA1 at 1:500 in 1% BSA/PBS
at 4uC on shaker overnight. Following antibody incubation the
membrane was washed three times with PBST and then incubated
with donkey anti-mouse antibody conjugated with IRDye800
(Licor) at 1:40,000 in 5% NFDM/PBST at room temperature for
90 minutes. The membrane was then scanned using an Odyssey
(Licor) imaging system.
For the Immunoprecipitation-Immunoblot experiments, SDS
was omitted from the lysis buffer to minimize the disruption of
antigen-antibody interaction. Immunoprecipitation was per-
formed as described in the mass spectrometry method section.
The gel was transferred to nitrocellulose membrane and probed
with DBA conjugated with alkaline phosphatase (EY Laboratories)
at 1:100 in PBST for 90 minutes at room temperature. The
membrane was then washed three times with PBST and developed
with BCIP/NBT color development substrate (Promega). The
image of the membrane was scanned using a desktop scanner. For
double labeling with SalmonE and 73.18 (CST1 reactive; [10,11],
samples were run in 6% SDS-PAGE gel with 3% stacking gel. The
membrane was probed with 73.18 (1:20) then with anti-mouse
IRDye700 (1:20000). After the membrane was scanned, it was re-
probed with SalmonE (1:100) then rat anti-mouse IgE antibody
(1:2000) then anti-rat IRDye800 (1:20000).
Parasite growth assay
For WT and Dcst1 parasites, a growth assay was performed
using a previously described 3H-uracil incorporation method [32–
34]. Since mammalian host cells are not capable of uracil uptake
but T. gondii is [33,34], the incorporation of radio-labeled uracil is
used to measure the growth of parasites. Briefly, HFF monolayers
in 12-well tissue culture plates were infected (100 or 10,000
parasites/well) in either pH 7.1 or pH 8.1 medium and incubated
in 5% or 0.5% CO2 respectively. Cells were incubated with 1 ml
of 2 mCi/ml 3H-uracil per well for 24 hours before the each
harvest time point. At 24, 48, 72, or 96 hours after infection,
medium was removed and cells were lysed with 1% SDS and
100 mg/ml of unlabeled uracil in PBS on ice. Nucleic acids were
precipitated with 10% trichloroacetic acid on ice for 2 hours. The
contents of each well were filtered with the glass fiber filters. The
radioactivity of 3H on the filter was measured with a scintillation
counter.
For assessment of Dcst1::cst1 and Dcst1::cst1Dmuc parasite growth,
microscopic observation of the growth of intracellular parasites
was used, as the disruption of the UPRT gene locus results in
parasites that no longer incorporate uracil. Parasites were grown
as described above then fixed in 4% paraformaldehyde,
permeabilized with 0.2% TritonX100 and probed with anti-
GRA1 antibody to visualize the parasites. For pH 8 (bradyzoite
permissive condition) a total of 600 host cells were examined
for each time point/condition and the number of intracellular
parasites per 600 cells determined. Bradyzoite vacuoles have been
reported to be resistant to lysis so direct counting of vacuoles
was used to evaluate growth. For pH 7 (tachyzoite permissive
condition) parasites were grown as described above (10,000
parasite initial inoculum), cells were scraped from each well of a
24 well plate, centrifuged and then re-suspended in 100 ml of 0.5%
saponin/PBS, pipetted 20 times to ensure host cell lysis and then
counted in a Neubauer hemocytometer in triplicate.
Parasite challenge, cyst count, and histology
Female 4 to 8 week old C57/BL6 mice (Jackson Laboratory)
were infected with 200 tachyzoites intraperitoneally. Any observed
mortality was recorded until 28 days after infection when the mice
were sacrificed and brains harvested. Brains were fixed in 4% PFA
in PBS overnight. Right brain halves were partially homogenized
with a syringe with PBS into 600 ml suspension then 120 ml were
counted under fluorescent microscope. Left halves of each
brain were fixed in 10% neutral buffered formalin for additional
72 hours and processed for paraffin embedding. Samples for
histopathology were sectioned to a thickness of 5 mm and stained
using hematoxylin and eosin (H&E) stains. Slides were analyzed
for the presence of tissue cysts, inflammation, and gliosis by light
microscopy and graded on a scale of 0–5 (where 0 = no lesions;
1 = minimal lesions; 2 = mild lesions; 3 = moderate lesions;
4 = marked lesions; and 5 = severe lesions). Sections were graded
by the pathologist in a blinded fashion to avoid confirmation bias.
Deep RNA sequencing (RNA-seq)
HFF cells grown in seven 150 mm tissue culture plates were
infected with parasites for each strain WT Pru, Dcst1, Dcst1::cst1
and Dcst1::cst1Dmuc in regular medium (pH 7 DMEM with 10%
fetal bovine serum, incubated in 5% CO2). Eight hours later, free
parasites were removed by washing with PBS and replaced with
regular medium (pH 7, 5% CO2) or differentiation medium
(pH 8.1 DMEM with 1% fetal bovine serum, 10 mM HEPES,
incubated in 0.5% CO2). Three days after the infection, cells were
harvested, passed through 27G needle twice to lyse HFF cells and
filtered through 3 mm pore polycarbonate membrane to remove
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HFF cells. This separation process was performed on ice. Purified
parasites were pelleted at 10006g for 15 minutes 4uC.
RNA was extracted using TRIzol Reagent (Invitrogen),
followed by genomic DNA removal and cleaning using RNase-
Free DNase Set kit and Mini RNease kit (Qiagen). Integrity of
the RNA samples was assessed using the Aligent 2100
Bioanalyzer. RNA samples having RNA Integrity Number
between 9 and 10 were used in this work. MicroPoly(A)Purist
Kit (Ambion) was used for enrichment of transcripts. The SOLiD
Total RNA-Seq Kit was used to construct template cDNA for
RNA-Seq following the protocol recommended by Applied
Biosystems. Briefly, mRNA was fragmented using chemical
hydrolysis followed by ligation with strand specific adapters and
reverse transcription was used to generate cDNA. The cDNA
fragments, 150 to 250 bp in size, were subsequently isolated by
electrophoresis in 6% Urea-TBE acrylamide gel. The isolated
cDNA was amplified through 15 amplification cycles to produce
the required number of templates for the SOLiD EZ Bead
system, which was used to generate the template bead library for
ligation base sequencing by the either SOLiD4 or 5500xl SOLiD
instrument (LifeTechnologies). The 50-base short read sequences
produced by the SOLiD sequencer were mapped in color space
using the Whole Transcriptome analysis pipeline in Life
Technologies LifeScope software version 2.5 against the genome
of T. gondii strain ME49 using the default mapping setting. Both
Fasta and GFF files were obtained from ToxoDB website (www.
toxoDB.org; Release 6.1). The output of the Whole Transcrip-
tome analysis generated (1) a gene counts file, with the base
counts summed to a single value across the entire gene length,
and with a RPKM value also given for each gene; (2) a BAM file
containing the sequence of every mapped read and its mapped
location; (3) two pairs of *.wig files (one pair for the two strands
on each chromosome) giving the mapped counts at each base
position; and (4) a statistics summary on alignment and filtering
report. Fold change in gene upregulation at bradyzoite induction
was calculated by dividing the RPKM values of pH 8.1 by that of
pH 7. The genes with low level expression (RPKM,5) in pH 8.1
WT parasites were removed. The top 50 genes that were
upregulated in WT parasites were plotted with gplot heatmap.2
in R.
Supporting Information
Figure S1 (A) Schematic of 59 locus for the
TGME49_064660 (cst1) gene. This figure shows the 59 region
of TGME49_064660 (cst1) locus. The blue region is the 59 UTR
that was experimentally determined using 59 RACE. The brown
arrows indicate the predicted start site (from www.ToxoDB.org),
which does not contain the signal sequence, and the putative
upstream start site, which includes the predicted signal sequence.
The number indicates the number of nucleotides from the end of
upstream gene TGME49_064670. (B) Presence of CST1
genes in parasites. PCR was performed (upper panel) with
genomic T. gondii DNA using primers flanking an intron and the
mucin domain in order to show the presence of the genes. The
amplicon size expected from each version of cst1 gene is: gDNA
1824 bp, cDNA 1546 bp, cDNADmuc 781 bp. A second PCR was
performed (lower panel) with primers upstream of cst1 and in the
center of the selectable marker HXGPRT to demonstrate the
insertion of the Dcst1 vector into the cst1 locus (1321 bp). (C) RNA
sequencing data demonstrating the expression of CST1
genes. Sequence reads of pH shocked parasite RNA mapped
to TGME49 genome (ToxoDB) at the cst1 locus. Type I strain
(RH) and Type II (ME49) both express cst1 mRNA. The cst
knockout (Dcst1) does not express CST1, whereas the wild type
(WT), cDNA complement (Dcst1::cst1) and mucin null complement
(Dcst1::cst1Dmuc) all express CST1.
(PDF)
Figure S2 SalmonE and DBA. (A) Parasite total lysate (same
membrane as Figure 2) was probed with DBA lectin. Both mAb
SalmonE (green) and DBA lectin (red) react with the same high
molecular band (CST1). Lower green bands (at the 25 kDa) are
GRA1 used as a parasite loading control. (B) mAb SalmonE
Densitometry. Densitometry measurements for each band and the
normalized CST1 expression level (CST/GRA1) for each lane are
shown in the following table and figure.
(PDF)
Figure S3 CST1Dmuc protein is expressed and localized
to the cyst wall. HFF cells were infected with either WT or
Dcst1::cst1Dmuc parasites and probed with anti-CST1 antiserum
(red) and DBA (green). This demonstrates that the CST1Dmuc
protein is expressed and localized to the cyst wall, that DBA lectin
binding is lost in CST1Dmuc parasites.
(PDF)
Figure S4 Histology of infected murine brains. (A)
Hematoxylin and eosin (H&E) stained brain sections were scored
for meningoencephalomyelitis using a scale of 0 to 5 (n = 4).
p,0.05 WT vs Dcst1::cst1Dmuc. (B) Brains from mice infected with
WT, Dcst1, Dcst1::cst1, or Dcst1::cst1Dmuc parasites for 4 weeks were
sectioned and stained with H&E. Photomicrographs were
obtained at 46, 106 and 206 magnifications. Tissue cysts are
indicated by a red arrow on 206magnification images.
(PDF)
Figure S5 Parasite growth measured at pH 7.0. A.
Growth measurement using 3H Uracil. Growth of WT (blue) or
Dcst1 parasites (red) in HFF cells (10,000 parasites per well at time
zero) at pH 7 was measured as 3H-uracil incorporation into
parasite DNA. Mean and standard deviation are shown. n = 3.
This experiment was repeated 3 times and had similar results for
wells harvested in triplicate. B. Growth measurement by counting
parasites. Growth of WT (blue), Dcst1 (red), Dcst1::cst1 (green),
Dcst1::cst1Dmuc (yellow) parasites at pH 7 culture condition was
measured by lysing the host HFF cells with 0.5% saponin and
counting the free parasites in a hemocytometer.
(PDF)
Figure S6 Immunoblot using SalmonE and 73.18 to R5,
ME49 and Pru strains of T. gondii and to Dcst1 and
Dsrs13 strains in PruDku80 T. gondii. This demonstrates
that mAb SalmonE binds to several type II strain T. gondii
parasites and that a similar sized band is seen in these parasites.
It also demonstrates that monoclonal 73.18 binds to this high
molecular weight band (recognized by SalmonE) as well as a
smaller band that we have identified as SRS13 (Tomita and
Weiss unpublished).
(PDF)
Table S1 List of top 50 upregulated genes in brady-
zoites. Gene up-regulation was determined by the RNA-seq
RPKM value at pH 8 divided by that at pH 7. The genes are
listed in order of highest upregulation. Gene ID and correspond-
ing descriptions are from ToxoDB.
(PDF)
Table S2 Primers used for construction of plasmids for
the deletion and complementation of CST1.
(PDF)
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